- $55.15m
- $64.20m
- $0.20m
Clene Inc. reports results for the quarter ended in December - Earnings Summary
Brief: Clene Reports Full Year 2022 Financial Results
U.S. STOCKS ON THE MOVE-Vertex Pharma, Duluth, Molecular Templates
U.S. STOCKS ON THE MOVE-BJ's Wholesale, FuelCell Energy, Holley
Brief: Cnm-Au8 Associated With Delayed Time To Key Clinical Progression Events At Six Months In Als Platform Trial
Clene rises on promising data from ALS drug trial
Clene Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Clene Inc Enters Purchase Agreement With Lincoln Park Capital Fund LLC
Brief: Clene Reports New Data From The Visionary-MS Phase 2 Study In Multiple Sclerosis Demonstrating Cnm-Au8® Treatment Improved Brain Neuronal Structural Integrity
Brief: David Matlin Reports 7.6% Stake In Clene Inc
Brief: Clene Reports Topline Results Of Phase 2 Covid-19 Study Of CNM-ZnAg
Clene slumps as COVID treatment fails in mid-stage study
Brief: Clene Enters Into Amendment No. 1 To Equity Distribution Agreement
Brief: Clene Reports Third Quarter 2022 Financial Results And Recent Operating Highlights
Brief: Clene Announces $10.8 Million Registered Direct Offering And $5 Million Debt Facility From The State Of Maryland
U.S. RESEARCH ROUNDUP-Box, Carmax, Docusign
U.S. STOCKS ON THE MOVE-Silver miners, KBR, Regeneron
U.S. STOCKS ON THE MOVE-Coinbase, Peloton, Viasat
Clene falls as ALS drug fail to meet main goal in mid-stage study